Azilsartan
From Self-sufficiency
| File:Azilsartan medoxomil.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7-carboxylate | |
| Identifiers | |
| CAS Number | 863031-21-4 |
| ATC code | none |
| Chemical data | |
| Formula | C30H24N4O8 |
| Molar mass | 568.5[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Azilsartan (INN) is an angiotensin II receptor antagonist undergoing research for the treatment of hypertension.
As the prodrug azilsartan medoxomil (INN, codenamed TAK-491), it was developed by Takeda. As of 2010[update], phase III clinical trials have been completed, and the drug is under review by the U.S. Food and Drug Administration.[1][2]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
- ↑ "Complete list of clinical trials for azilsartan (ClinicalTrials.gov)". Retrieved 2008-06-20.
- ↑ Collins TR (2010-08-02). "New ARB shows good results in blacks". Medscape. Retrieved 2010-08-02.
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from 2010
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- Angiotensin II receptor antagonists
- Benzimidazoles
- Oxadiazoles
- Carbamates
- Ethers
- Cardiovascular system drug stubs
- 2Fix
